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CSF reduces the hematological toxicity and supportive care 
requirements in recipients of autologous and allogeneic trans- 
plants. In our staldy we combined G-CSF and GM-CSF to mobi- 
lize PBPC for transplantation. Method: A total of 21 subjects par- 
ticipated in the study. Seven patients had neuroblastoma stage IV; 
6 had stage IV Hodgkins lymphoma; 2 had second remission acute 
myeloid leukemia; 2 had third remission acute lymphoblastic 
leukemia; 1 had second relapsed rhabdomyosarcoma, and 1 with 
myelodisplastic syndrome. There were 2 normal donor children. 
All were under 18 years old. All the patients were mobilized with 
G-CSF & GM-CSF, 10ug/kg/d x 5 days each, followed by PBPC 
harvesting until a threshold of 2.0xI06/Kg CD34+ cells was 
obtained. A total of 11 autologous and 2 allogeneic PBPC trans- 
plants were performed. Results: Data on PBPC 24, 48, 72, and 
96hrs after the fifth dose of cytokines are shown in the below 
table: Six patients required 2 apheresis, 7 required 3, and 7 
required 4 apheresis to achieve our goal. For the 11 PBPC autolo 
gous transplant patients, the median days to get an 
ANC>500/mm 3 was 9.8 days; 9.5 days for the allogeneic. Median 
days to platelets engraftment was 11.5 days for the autologous 
PBPC; 12.5 for the allogeneic. None of the subjects experience 
bone pain, headache, flu like side effects or a documented o 
proven infection. Conclusions: The combination of G-CSF & 
GM-CSF (10ug/kg/day x 5 days) is well tolerated. It contrived a
clinical reduction in the degree and duration of severe neutropenia 
and thrombocytopenia in both allogeneic/autologous transplants. 
It seems to be cost effective and adequate to mobilize more than 
an average numbers of PBPC(2-3 apheresis) to perform allogene- 
ic/autologous hematopoietic ransplant in pediatric population. 
Parameter 24 48 72 96 Total 
Mean #CD34+x10exp6/kg 4.47hrs 3.87hrs 2.12hrs 1.20hrs 11,65 
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CLINICAL AND QUALITY OF LIFE MONITORING IN MULTIPLE SCLE- 
ROSIS PATIENTS UNDERGOING HIGH DOSE CHEMOTHERAPY AND 
AUTOLOGOUS STEM CELL TRANSPLANTATION 
Novik, A.AJ; IoTmva, T.I/; Lisz~kov, I.A.:; Kulag~l, A.A.:; Malysheva, 
O.A.e; Bisag~, G.N.~; 3/lelTlicheTzko, U.I'~1; Chelombit, L.f'U; Kish- 
tovich, A.I.~I; Osipova, N.EJ 1. Rassimz Cboperative Group of High 
Dose ChemotheT:apy iJ~ AuroimmuT~e Diseases, St.Petersbm'g, Rnssia~ 
Fe&ratiom 2. Russian Coopelvltive Group of High Dose Chemother~ W 
ilz ~'tlttoi77177zlt't~e Diseases, Novosibh's/e, Rltsskl~7 Federatiol~. 
High dose chemotherapy (HDCT) with autologous tem cell 
transplantation (ASCT) is a new treatment strategy for patients 
with multiple sclerosis (MS). Quality of life (QoL) is increas- 
ingly used as a treatuaent outcome along with traditional clini- 
cal outcomes. Monitoring of clinical and QoL outcomes of 
HDCT and ASCT in MS patients is worthwhile. The aim was 
to provide monitoring of clinical outcomes and QoL parame- 
ters in MS patients before and at different ime-points after 
ASCT. Seven patients with MS, who underwent HDCT and 
ASCT within Russian Cooperative Group of High Dose 
Chemotherapy in Autoiminune Diseases, were enrolled in the 
study. All the patients previously underwent conventional 
treatment. The transplantations were performed in accordance 
with EBMT protocols. MRI was carried out before APSCT 
and repeated every 6 months. QoL was assessed by Russian 
versions of QoL questionnaires: FACT-BMT - specific for 
patients with BMT, FAMS - specific for MS patients. QoL and 
EDSS evaluation were provided at baseline, at discharge, and at 
3, 6, 8, 12 months and eve W 6 months following ASCT. Fol- 
low-up period varied from 6 to 36 months (one patient - 6 
months, three patients -18 months, two patients - 24 months, 
one patient 36 months). Stabilization of the disease was 
achieved in six cases: in four patients no new lesions on MRI 
were observed, in two patients a decrease in the number of 
lesions took place. In one patient one new lesion appeared 1.5 
years after APSCT. Comparison of EDSS before ASCT and at 
follow-up revealed its decrease in 6 patients; in one patient it 
remained the same and in the patient with disease progression 
EDSS increased (from 6.5 to 7.0). Distinct QoL improvement 
was observed in all the patients with disease stabilization at the 
end of follow-up. QoL improvement on the majority of scales 
was achieved within 3 months after ASCT as compared to 
baseline with a tendency to further improvement a late follow- 
up. Definite QoL improvement was documented at one year 
after ASCT and remained stable throughout the later follow- 
up in the patients with long-term follow-up. HDCT and 
ASCT in patients with MS resulted in disease stabilization in 
six out of seven patients under observation. Along with clinical 
improvement distinct increase of QoL parameters in MS 
patients took place. 
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QUALITY OF LIFE IN PATIENTS WITH CHRONIC GRAFT VS HOST DIS- 
EASE: A QUALITY PROCESS IMPROVEMENT IN BLOOD AND MAR- 
ROW TRANSPLANTATION 
Neumam~, if.£.; Hsa, Y.; Tallarigo, ft.; ChampliJ~, R.; Coltriel, D. 
Blood and Marrow 7)'a~splmmttion, U iversity of Texas MD Anderson 
CmTcer CenTre1", HoustoT~, TX. 
Chronic Graft vs. Host Disease (cGVHD) occurs in approxi- 
mately 50% of post allogeneic blood and marrow transplantation 
(BMT) patients. The effects can be devastating to patients, who 
have survived this aggressive treatment regimen to cure or control 
their malignancies. At our comprehensive cancer center, the 
GVHD clinic MD, APN and/or PA evaluate patients with 
cGVHD referred by other BMT or community physicians. The 
clinic uses a multidisciplinary approach to provide patients com- 
prehensive assessment and treatment for the physical and psy- 
chosocial issues. During the initial assessment the patients com- 
plete the FACT-BMT (Functional Assessment of Cancer 
Therapy) and the MDASI (MD Anderson Symptom Inventory) to 
help identify quality of life (QOL) issues. The FACT-BMT is a 
50-item (0-4 scale) instrument measuring QOL with subscales 
including physical, social/family, emotional and functional wel
being as well as items, addressing BMT related issues (infertility, 
eyesight, memory, regret about BMT, cost, family hardship). 
Higher scores indicate improved the QOL. The tool developed by 
Cella has demonstrated reliability and validity. The MDASI is a 
13-iteln (0-10 scale) tool that measures ymptoms experienced. 
The outcomes data on 36 cGVHD patients who were 6 months to 
12 years post BMT indicated the following results: patients expe- 
rienced the greatest alterations in the functional, physical, and 
emotional domains. The majority (97%) experienced problems 
with skin, blurred vision (73%), hardship on family (71%), memo- 
I T (69%) and financial burden (67%). The data from the MDASI 
indicated the 5 most frequently reported symptoms to be: fatigue 
(73%), sleep disturbance (70%), sadness (70%), drowsiness (67%), 
and dry mouth (64%). With information from the QOL tools and 
comprehensive physical examination, patient referrals were expe- 
dited. Improvement in patients QOL with sequential dministra- 
tion of the tools demonstrates the importance of this GVHD mul- 
tidisciplinary clinic approach. 
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PERFORMANCE OF YOUNG LONG TERM SURVIVORS AFTER ALLO- 
GENEIC STEM CELL TRANSPLANTATION (SCT) 
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B3/iT-mzit, Rigshospitalet, CopenhdgeJ~, Demnavk. 
Purpose: To examine overall performance of adolescents and 
young adults who have survived long" term after allo-SCT. Perfor- 
mance was estimated by means of Lansky and Karnofsk T scores. 
Patients & methods: Patients were all transplanted at the same 
BMT unit between1987 and 1997. Age at transplant was 10 to 30 
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